Editor's key points † This study aimed to analyse the cost of re-exploration for bleeding after coronary artery bypass graft surgery. † The results were then used to analyse the net cost of haemostatic treatment and the influence of preoperative antiplatelet therapy. † Re-exploration increased hospital costs, mainly because of the prolonged hospital stay and the cost of surgical revision. † The cost of haemostatic drugs contributed little to the total, suggesting that clinical interventions to prevent haemorrhage might be underutilized.
haemostatic interventions such as rFVIIa and to investigate the influence of preoperative antiplatelet drugs such as clopidogrel on costs.
Methods

Study design and population
We performed a retrospective study of all patients undergoing surgical re-exploration for bleeding after isolated CABG at three cardiothoracic centres in Sweden: Linkö ping University Hospital, Uppsala University Hospital, and Ö rebro University Hospital. These university hospitals are the only referral centres in their respective regions of Sweden, serving a total population of 2.9 million. Data from patients receiving surgery during the period January 1, 2005-December 31, 2008 were analysed. The Regional Ethics Review Board, Uppsala, approved the study.
The study had a case -control design. Each patient re-explored for bleeding was matched with two controls who were not re-explored for bleeding. Data for matching were compiled from each hospital's database of patients undergoing isolated CABG during the study period. The controls were selected according to the following six matching criteria: centre, age +1 yr, gender, presence of diabetes, number of peripheral anastomoses, and BMI (the patients were categorized into groups according to the WHO classification of overweight and obesity). Of the patients fulfilling the matching criteria, the two receiving surgery closest in time to the case were chosen as controls.
Data for patients included in the case -control study were retrieved from the patients' records and the hospitals' databases. Both cases and controls were excluded if they were in cardiogenic shock before operation, required emergency operations, required preoperative treatment with inotropic drugs, had extracorporeal circulation for .160 min, required preoperative dialysis, or required second or subsequent surgery. The exclusion criteria were chosen to exclude patients whose re-exploration for bleeding might be the consequence of a generally complicated intra-or postoperative course.
Definitions
Cases were defined as patients undergoing re-exploration for bleeding, regardless of the amount of blood lost in chest tubes. The decision to re-explore was at the discretion of each surgeon on call. No individual surgeon was responsible for more than 5% of patients. Postoperative myocardial infarction was defined as creatine kinase-myocardial band on day 1 of .50 mg litre 21 . The intermediate care unit
allowed invasive monitoring and infusion of vasoactive drugs but not mechanical ventilation.
Data collection and cost assessment
Clinical data and hospital-related postoperative resource utilization were analysed to study differences in the patients' characteristics and the cost structure. The cost analysis was based on resource utilization from the completion of the primary CABG operation until the patients were discharged home or to a nursing home from the referring hospital. The following resources were recorded: duration of stay in the ICU and postoperative ward; volume of all blood transfusions; amounts of coagulation factor concentrate and haemostatic drugs used; and occurrence of all re-operations under general anaesthesia for any indication, for example, re-operation for sternum wound infection. Data were transformed into costs by applying a unit cost from each hospital's internal economic system. The costs used in the calculations are shown in the Appendix. As the study was performed at three cardiothoracic centres, the mean cost for these items was used. Resource utilization data are presented as means (SD). Non-parametric bootstrap analysis was applied to assess the accuracy of the cost estimate and differences in costs between groups due to skewed cost distributions. 23 24 All tests of statistical significance were two-tailed, and a probability value of 0.05 was considered to be statistically significant. Correction for multiple comparisons was not applied. The mean cost (mC) of re-exploration per patient in the total population was calculated as:
where F is the frequency of re-exploration for bleeding in the total cohort.
The estimated cost reduction per patient in the total population (△C) as a result of prophylactic therapy after CABG surgery was calculated as:
where F is the frequency of re-exploration for bleeding (without prophylactic therapy) in the total cohort and E the efficacy of prophylactic therapy, that is, the relative reduction in the risk of re-exploration as a result of post-CABG prophylactic therapy (%), and F×E/100 the absolute risk reduction. The net cost per patient for drug intervention post-CABG to prevent bleeding¼Cp -(F×E/100×cost for re-exploration), where Cp is the cost of drug treatment.
Cost analysis of re-exploration for bleeding 
Results
Clinical outcomes
During the study period, 4232 patients underwent isolated primary CABG surgery and, of these, 3.5% (148 patients) were re-explored for bleeding and 3% (127 patients) fulfilled the inclusion criteria in the case -control study. These 127 patients and 254 control patients were included in the study (total 381; Table 1 ). There were no differences in preor postoperative laboratory values between the groups, except for slightly lower postoperative haemoglobin levels among the cases (Tables 1 and 2 ). Nor were there any differences in operation times, extracorporeal circulation times, aortic cross-clamp times, or peri-operative antifibrinolytic treatment between the groups (Table 2) . Patients undergoing surgery for bleeding were more likely to have had urgent CABG surgery (Table 1) and were significantly more likely to have received clopidogrel (Table 1) . Thirty-one per cent of the patients re-explored for bleeding (39/127) were exposed to preoperative clopidogrel within 5 days of CABG surgery, compared with 18% of the control group (47/254). Besides clopidogrel, there were no significant differences in preoperative anticoagulation treatment.
Resource utilization
After CABG surgery, the re-explored patients received more blood transfusions than the controls (Table 3) . Despite this, postoperative haemoglobin levels were slightly lower in the re-explored patients. These patients were also more likely to receive tranexamic acid, desmopressin, and fibrinogen after operation (Table 3 ). Patients re-explored for bleeding were treated for a longer time with mechanical ventilation [mean 1247 (1535) vs 494 (2061) min, P,0.01], and a longer stay in the ICU ( Table 3 ). The incidence of postoperative myocardial infarction was higher in patients re-explored for bleeding and they received postoperative antibiotic treatment more often. However, there were no differences in the incidence of sternal wound infections. There was a trend towards increased mortality (≤30 days after CABG surgery) among the re-explored patients (see Table 3 for details).
Resource utilization is shown in Table 3 . Cases had significantly higher resource utilization. The total mean cost for a patient re-explored due to bleeding was E19 642 (14 030) and for patients not re-explored E13 350 (13 215). The mean difference between cases and controls, translated into cost, is shown in Table 4 . The mean increase in cost for a patient undergoing re-exploration for bleeding compared with the cost for controls not requiring re-exploration was E6290. The bootstrap analysis showed similar results to the parametric analysis (mean difference E6281). Of the increase in costs, 48% was due to the prolonged stay in the ICU and the ward (mean increase in hospital stay of 2.8 days), 31% was due to the cost of surgery and general anaesthesia, 20% was due to the increased number of transfusions, and 1.6% was due to treatment with haemostatic drugs.
Cost model for prophylactic treatment
The theoretical cost of prophylactic treatment, and the cut-off point where this cost would be neutralized by a reduction in the incidence and therefore cost of re-explorations, can be plotted as a function of the expected rate of re-exploration without prophylaxis, as in Figure 1 . The possible impact of preoperative clopidogrel treatment on the cost of re-exploration is shown in the figure. The incidence of re-exploration was 5.1% for patients treated with clopidogrel and 2.5% for patients not treated with clopidogrel.
The cost of a single 40 mg kg 21 dose of rFVIIa for a person of 70 kg was E1697. Figure 2 shows the net cost of treating a patient with 40 mg kg 21 rFVIIa, depending on the expected risk of re-operation without this prophylactic treatment and the estimated efficacy of the drug (using the formula in the Cost analysis of re-exploration for bleeding Methods section). For example, if there was a 50% expected risk of re-exploration without prophylaxis and if rFVIIa was effective in 50% of patients, the net cost of prophylaxis would be zero. Thus, to be cost neutral, treatment of four patients with prophylactic haemostatic drugs would need to result in one avoided re-exploration. The net costs of prophylactic treatment per patient in a given population will increase as the estimated risk of re-exploration without prophylaxis decreases.
Discussion
In this study, the increase in postoperative costs for a patient undergoing re-exploration surgery for bleeding was E6290 compared with an uncomplicated, first-time, isolated CABG operation in Sweden. The prolonged stay in the ICU and the recovery ward accounted for half of the added cost, one-third was due to the costs of surgery, one-fifth was due to the increased costs of transfusions, and ,2% was due to haemostatic drug treatment.
As there are differences in costs between different healthcare systems, direct comparison of the observed costs between studies can be misleading. 25 This study was performed in three not-for-profit hospitals, and government tax funding covered all the costs. As these hospitals serve all patients undergoing cardiac surgery in their respective region, there is no referral selection bias. According to Herwaldt and colleagues, 4 the attributable cost for haemorrhage in the USA was 3866 USD overall, 9912 USD (≈E7136) for patients requiring re-exploration and 3316 USD for those treated medically. The median attributable postoperative length of stay was 1 day. In the US Medicare programme, which involves 114 233 patients, the incremental cost of any re-exploration was 15 353 USD (≈E11 208), resulting in an incremental length of stay of 3.1 days. 26 However, in a recent study from Germany by Christensen and colleagues, 3 the incremental cost of excessive postoperative bleeding in cardiac surgery was E6251.
There is an association between preoperative treatment with antiplatelet drugs and the incidence of re-exploration. 13 -16 As preoperative drug treatment with antiplatelet drugs has evolved, an increasing number of patients have cardiac surgery within 5 days of discontinuing drug treatment with clopidogrel in combination with aspirin. 27 Intraoperative treatment with the serine protease inhibitor aprotinin reduces pre-and postoperative blood loss. 28 However, as this drug has been withdrawn from the market, alternative treatment with tranexamic acid, platelet transfusion, or even rFVIIa in difficult cases may be necessary to treat diffuse bleeding diathesis in this category of patients. An intervention to prevent bleeding would be costeffective if the increase in cost is equal to the value of the clinical benefit obtained. The intervention would be cost saving if the hospital's cost saving exceeds the cost of the intervention, or would be cost enhancing if the intervention increases the hospital's costs. Haemostatic drugs may be underutilized in association with cardiac surgery because of budget concerns. For example, rFVIIa is expensive but potentially effective in reducing postoperative bleeding. In a recent study, rFVIIa given after CABG surgery was associated with a 50% reduction in the relative risk of re-exploration 29 when compared with placebo. Under the same assumptions, and applying the estimated cost of re-exploration from our study, prophylactic treatment of four patients with 40 mg kg 21 rFVIIa would need to result in one avoided re-exploration to be cost neutral. The net cost of prophylaxis should be balanced against the expected benefit for the patient. The number of transfusions is reduced by rFVIIa, and multiple blood transfusions are reported to decrease both short-and long-term survival and increase morbidity. 31 and as the reported efficacy of the drug varies in earlier reports, further prospective studies of the efficacy of rFVIIa are warranted. Speir and colleagues measured the additional costs of postoperative complications for 14 780 patients undergoing CABG surgery in the USA. In their study, re-exploration for bleeding increased the costs by 76% compared with the baseline cost, that is, the cost for patients without postoperative complications. 32 In our study, the mean cost for a patient re-explored for bleeding was 47% higher than the average cost of isolated primary CABG operations in Sweden without re-exploration. We excluded patients in preoperative cardiogenic shock, those receiving emergency operations, those receiving preoperative treatment with inotropic drugs, those with extracorporeal circulation for .160 min, those requiring preoperative dialysis, and those requiring second or subsequent surgery. The exclusion criteria were chosen to select cases where increased costs could be assumed to be caused by the bleeding requiring re-operation per se, rather than as a consequence of a generally complicated intra-or postoperative course. Accordingly, excess costs in more complicated situations were not analysed. Increases in the incidence of complications such as stroke, infections, and renal failure secondary to bleeding and blood transfusion were expected but were not obvious in our study. The number of patients in our case -control study may have been too small to detect any differences, and the exclusion criteria may also have contributed. Thus, the calculated cost of re-exploration in this study may have been underestimated. Also, costs after discharge from the referring hospital were not included.
In conclusion, re-exploration for bleeding after isolated CABG surgery increased hospital costs substantially, mainly because of the prolonged stay in hospital and the cost of surgical revision; the cost of haemostatic drugs contributed little to the total. Our cost analysis suggests that clinical interventions to prevent haemorrhage might be underutilized. 
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